ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Articles tagged "Nephrotoxicity"

  • 2020 American Transplant Congress

    Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy

    A. Gamilla-Crudo, S. Hussain, A. Rizvi, R. Ramirez, M. Kueht, H. Stevenson-Lerner, J. Fair, M. Mujtaba

    UTMB, Galveston, TX

    *Purpose: Thrombotic microangiopathy (TMA) can happen after kidney transplant. It may occur de novo or as a recurrent disease. De novo is usually associated with…
  • 2020 American Transplant Congress

    Belatacept Conversion: Are Patients BENEFIT-ing

    R. Crew, S. Mohan, S. S. Patel

    Columbia University Irving Medical Center, New York, NY

    *Purpose: Belatacept is increasingly used in renal transplant recipients experiencing adverse effects from calcineurin inhibitors(CNI) despite limited medium- and long- term data on safety and…
  • 2020 American Transplant Congress

    Clinicopathological Evaluation of Long-Term Survivor More Than 10 Years after Living Kidney Transplant with Corticosteroid Early Withdrawal Protocol

    H. Sasaki1, T. Tanabe1, H. Higuchi1, T. Tsujimoto2, H. Harada1

    1Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, 2Pharmacy, Sapporo City General Hospital, Sapporo, Japan

    *Purpose: We have previously reported that favorable short-term outcomes of kidney recipients were achieved by corticosteroid early withdrawal protocol (CSEW) compared to the conventional protocol…
  • 2020 American Transplant Congress

    Metformin Improves Biomarkers of Calcineurin Inhibitor Related Nephrotoxicity

    M. R. Fernando, K. Taylor, S. Herath, A. Au, J. Erlich, Z. Endre

    Department of Nephrology, Prince of Wales Hospital, Randwick, Australia

    *Purpose: Calcineurin Inhibitors (CNIs) prevent transplant rejection but cause significant nephrotoxicity. Biomarkers of CNI nephrotoxicity could help drug dosing and improve long-term graft outcomes. As…
  • 2020 American Transplant Congress

    Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Treatment of Patients with Hepatitis B Following Liver Transplantation

    C. Cheng

    Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Kwei-Shan Township, Taoyuan, Taiwan

    *Purpose: Taiwan has a high prevalence of hepatitis B (HBV) and HBV related end-stages liver diseases are the leading causes of liver transplantation (LT). Tenofovir…
  • 2020 American Transplant Congress

    Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells

    H. J. Jang

    Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of

    *Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…
  • 2019 American Transplant Congress

    Discovery and Validation of an Early Post-Transplant Biomarker Model Predictive of Chronic Kidney Disease in Liver Transplant Recipients

    J. Levitsky1, S. Asrani2, G. Klintmalm2, T. Schiano2, A. Moss3, K. Chavin4, C. Miller5, L. Zhao6, K. Guo6, N. Bridges7, J. Odim7, M. Brown7, D. Ikle8, B. Armstrong8, M. Abecassis9

    1Gastroenterology and Hepatology, Northwestern University, Chicago, IL, 2Baylor, Dallas, TX, 3Mayo Arizona, Phoenix, AZ, 4Case Western, Cleveland, OH, 5Cleveland Clinic, Cleveland, OH, 6Northwestern University, Chicago, IL, 7NIAID, Bethesda, MD, 8Rho, Chapel Hill, NC, 9Comprehensive Transplant Center, Northwestern University, Chicago, IL

    *Purpose: A significant proportion of patients develop chronic kidney disease after liver transplantation (LT). We aimed to develop clinical/protein models to predict future GFR deterioration…
  • 2019 American Transplant Congress

    Renal Failure as a Complication of Vascularized Composite Allotransplantation

    R. N. Barth1, J. T. Shores2, G. Brandacher2, M. H. Levine3, A. Weissenbacher4, A. J. Nam1, N. Shockcor1, E. D. Rodriguez5, S. Schneeberger4, W. Lee2, S. T. Bartlett1, L. Levin3

    1University of Maryland School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Pennsylvania School of Medicine, Philadelphia, PA, 4Medical University Innsbruck, Innsbruck, Austria, 5New York University School of Medicine, New York, NY

    *Purpose: Vascularized composite allotransplantation (VCA) has demonstrated impressive outcomes in areas of extremity (UETx), face (FTx), genitourinary, and abdominal wall transplantation with up to twenty…
  • 2019 American Transplant Congress

    Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population

    B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar

    University of Illinois at Chicago, Chicago, IL

    *Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…
  • 2019 American Transplant Congress

    Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation

    I. R. Badell, P. Vasanth, A. B. Farris, J. M. Robertson, G. M. Karadkhele, C. P. Larsen

    Emory University School of Medicine, Atlanta, GA

    *Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
    • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    This site uses cookies: Find out more.